Home For VC Firms Blog About Us Contact Book a Free Consultation
For Life Sciences Venture Capital Firms

Your Portfolio Companies Deserve Operational Excellence from Day One

BioVertex Consulting partners with life sciences VC firms to provide hands-on program management, development strategy, and governance frameworks for early-stage through clinic-stage portfolio companies, building the operational backbone that protects your capital, accelerates milestones, and ensures your investments execute as well as their science.

Schedule a Portfolio Assessment Call
The Challenge

The Operational Gap That Burns Through Your Capital

Venture capital team in strategic discussion

You've invested in breakthrough science. The founding team has deep domain expertise, strong publications, and a compelling mechanism of action. But six months post-close, the board deck looks the same. The development plan hasn't matured. Cross-functional alignment is missing. And the timeline to IND keeps shifting.

This is the operational gap, and it's where early-stage biotechs lose time, credibility, and capital.

Most Seed and Series A biotech companies are built around scientific founders who excel at discovery but have limited experience managing the operational complexity of drug development. They need structured governance, rigorous milestone planning, and someone who has navigated IND-enabling studies, regulatory strategy, and cross-functional team leadership before.

The VC's Dilemma

You see the problem, but your options are limited. Hiring a full-time VP of Operations at this stage is premature and expensive. Your operating partners have bandwidth constraints across the portfolio. And the big consulting firms deliver strategy decks, not execution.

You need a partner who can do the work, not just advise on it.

How We Help

Embedded Operational Expertise Across the Investment Lifecycle

BioVertex works directly with your portfolio companies as a fractional member of their team, not as an outside advisor delivering a PowerPoint. We bring 20+ years of US pharmaceutical and biotech industry experience to help early-stage companies build operational muscle from the inside.

Pre-Investment

Pressure-Test the Plan Before You Commit Capital

Before you write the check, we help you evaluate whether the operational plan behind the science is sound.

  • Development Plan Assessment: We review the development roadmap for feasibility, timeline realism, and resource alignment. Are CMC, regulatory, and clinical workstreams properly sequenced? Are there hidden dependencies that could delay the program by 12+ months?
  • Operational Due Diligence: Beyond the science, we assess governance maturity, team structure, vendor readiness, and decision-making frameworks. We flag the operational red flags that traditional scientific diligence misses.
  • Budget & Resource Validation: We benchmark the proposed budget against comparable-stage programs and identify areas where the plan is over- or under-funded relative to the risk.
What You Get

A concise operational diligence memo with go/no-go recommendations, risk-ranked findings, and a prioritized remediation plan ready for Day 1 post-close.

Post-Investment

Build Operational Infrastructure in the First 90 Days

The first 90 days after funding are when operational habits get set. We help your portfolio companies build the right ones.

  • Stage-Gate Governance: We establish the review process, decision rights, and milestone-tracking cadence that give your board real visibility into progress. No more ambiguous status updates.
  • Integrated Development Timeline: The cross-functional Gantt chart mapping CMC, nonclinical, regulatory, and clinical workstreams with dependencies, critical path, and risk triggers clearly identified.
  • Target Product Profile (TPP): We define the TPP that aligns development decisions with commercial and regulatory realities from the start, so you're not re-engineering the plan at Phase II.
  • Board-Ready Reporting: Executive dashboards that give investors clear, data-driven updates on milestones, risks, budget burn, and upcoming decisions.
What You Get

A portfolio company that operates with the discipline of a Phase II organization from the moment the term sheet closes.

Ongoing

Fractional Leadership That Scales With the Program

Not every early-stage company needs a full-time operations leader. But every one needs operational leadership.

  • Fractional Head of Program Management: We serve as the day-to-day program leader, managing cross-functional teams, running governance meetings, and keeping the development timeline on track.
  • Fractional VP of Operations: For companies needing broader support including vendor management, SOPs, knowledge management, we provide the strategic layer between the CEO and the team.
  • Interim Leadership: When a portfolio company loses a key operations leader, we step in within days, not the weeks or months it takes to recruit a permanent hire.
What You Get

Senior-level operational capacity at a fraction of the cost, deployed within days, with no long-term commitment until the company is ready for a full-time hire.

Cross-Portfolio

Value Creation Across Your Entire Fund

When you work with BioVertex across multiple portfolio companies, we see patterns and opportunities that individual companies cannot.

  • Operational Best Practices: Standardized governance templates, reporting formats, and decision-making frameworks across your portfolio, creating consistency for your investment team and boards.
  • Shared Vendor Intelligence: Insights from across programs, including which CROs deliver on time, which CDMOs have capacity, which regulatory consultants perform in your therapeutic areas.
  • New Investment Onboarding Playbook: A repeatable "first 90 days" operational playbook you can deploy to every new portfolio company.
What You Get

A competitive advantage as a fund: your portfolio companies execute faster because they're not reinventing the operational wheel every time.

The BioVertex Difference

Why VC Firms Choose BioVertex

⚡

Execution, Not Just Advisory

We don't hand you a strategy deck and walk away. We embed with your teams and do the work: managing timelines, running governance meetings, building the TPP, drafting the board deck. We're practitioners, not presenters.

🧬

18+ Years of US Pharma & Biotech

Our team has navigated the full development lifecycle from IND-enabling studies through regulatory submissions across multiple therapeutic areas. We've managed programs inside large pharma and lean startups alike.

🚀

Built for Early-Stage Speed

A Seed-stage company with 8 employees doesn't operate like a Phase III organization with 200. Our frameworks are right-sized for your portfolio companies, lightweight enough to adopt quickly, robust enough to scale.

💰

Capital-Efficient Model

No six-figure SOWs or three-week scoping exercises. We start within days, price on a fractional monthly basis, and scale up or down as the program evolves. Your portfolio companies preserve cash for the science.

📊

VC-Fluent Communication

We think in terms of milestone de-risking, capital-efficient development, investment thesis execution, and board-ready deliverables. We communicate in the language your investment team speaks.

🔄

Day 1 Post-Close Readiness

We can be embedded with your portfolio company within 5 business days of engagement. No ramp-up period. We start with a structured assessment, align priorities with the CEO and your team, and begin executing immediately.

Ready to Strengthen Your Portfolio's Operational Execution?

Whether you're evaluating a new investment, looking to accelerate a portfolio company falling behind on milestones, or building operational standards across your fund, we'd welcome the conversation.

Schedule a 30-Minute Portfolio Assessment Call

Or email us directly: contactus@biovertexconsulting.com